One linked filing — more sources may join as they report · filed Oct 3, 2024. View entity profile → Other incidents for this victim →
Attribution, victim identity, and counts shown here derive from a threat actor's public extortion-blog claims, aggregated by ransomware.live. They have not been validated by the victim or any regulator. Treat them as the threat actor's assertion until a regulatory filing or victim disclosure corroborates them.
incident inc_b521bf58c565464c · merge_method deterministic
Not recorded for this incident
Discovery variance · Leak precedence · Materiality delta · SEC filing delay · Filing span — no SEC 8-K in this cluster; needs two dated filings.
all Leak Site
Earliest sighting first · deep chronology in Litigation Timeline
Lyomark Pharma was founded in Oberhaching, near Munich, in 1989 as a contract manufacturer and active ingredient manufacturer for niche products. As the name suggests, Lyomark supplies sterile lyophilised and liquid products, and has firmly established itself in this sector of the pharmaceutical industry over the last 25 years.
About this clustering
DisclosureLens links filings into incidents through layered matchers: deterministic rules (same source document, multistate filings of one breach, tight-window same-victim pairs), a weighted-similarity scorer for cross-source candidates, and an operator review queue for everything uncertain. Each link records its own method and confidence — shown per filing in the timeline below. The system defaults to NOT merging when uncertain, because a false merge (collapsing two unrelated breaches) is more harmful than a false split (showing related filings separately); uncertain pairs route to human review instead of auto-merging. Filing summaries shown in the timeline are AI-generated extracts — verify each against its linked source.